Designing a Delinked Incentive for Critical Antibiotics: Lessons from Norway

Abstract

No country has yet implemented a pilot to ensure access to or the innovation of new antibiotics for multi-drug infections. A team from national health agencies in Norway, with the support of the Innovative Medicine Initiative-funded project DRIVE-AB, designed a model suitable for the national context, including the selection of the antibiotics, the potential value, and the operational model.

Get full access to this article

View all access options for this article.

References

Laxminarayan

et al. , “Antibiotic Resistance: The Need for Global Solutions,” Lancet Infectious Diseases 13, no. 12 (2013): 1057-1098.

A. H.

Holmes

et al., “Understanding the Mechanisms and Drivers of Antimicrobial Resistance,” The Lancet 387, no. 10014 (2016): 176-187.

Laxminarayan

, “Antibiotic Effectiveness: Balancing Conservation against Innovation,” Science 345, no. 6202 (2014): 1299-1301.

L. L.

Silver

, “Challenges of Antibacterial Discovery,” Clinical Microbiology Reviews 24, no. 1 (2011): 71-109.

Pew Charitable Trust, Antibiotics Currently in Clinical Development, available at <http://www.pewtrusts.org/en/multimedia/data-visualizations/2014/antibiotics-currently-in-clinical-development> (last visited October 6, 2017).

DRIVE-AB, Work Package 2, Task 3: Identified Risks and Bottlenecks to Antibiotics Innovation (2015), available at <http://drive-ab.eu/wp-content/uploads/2014/09/Report-Bottlenecks-and-risks-DRIVE-AB-Task-3-20151023-FINAL.pdf> (last visited January 11, 2018).

AMR Review, Tackling Drug-Resistant Infections Globally: Final Report and Recommendations (2016), available at <https://amr-review.org/sites/default/files/160525_Final%20paper_with%20cover.pdf> (last visited January 11, 2018)

Daniel

et al ., “Addressing Antimicrobial Resistance and Stewardship: The Priority Antimicrobial Value and Entry (PAVE) Award,” JAMA 318, no. 12 (2017): 1103-1104.

The Boston Consulting Group, Breaking through the Wall: A Call for Concerted Action on Antibiotics Research and Development (2017), available at <http://www.bundesgesundheitsministerium.de/service/publikationen/gesundheit/details.html?bmg%5bpubid%5d=3006> (last visited January 11, 2018).

10.

Folkhalsomyndigheten, Analys av förutsättningar för att testa en ny ersättningsmodell för antibiotika (2016), available at <https://www.folkhalsomyndigheten.se/publicerat-material/publikationsarkiv/a/analys-av-forutsattningar-for-att-testaen-ny-ersattningsmodell-for-antibiotika/> (last visited Jan. 11, 2018).

11.

Legemiddelforbruk.no, Drug Consumption in Norway, available at <http://www.legemiddelforbruk.no/> (last visited May 1, 2017).

12.

Norwegian Competence Center for Antibiotic Use for Specialist Health Services, Nasjonal faglig retningslinje for bruk av antibiotika i sykehus, available at <https://helsedirektoratet.no/retningslinjer/antibiotika-i-sykehus> (last visited May 1, 2017).

13.

Norwegian Medicines Agency, Find Medicine, available at <http://www.legemiddelverket.no> (last visited Dec. 1, 2017).

14.

J. F.

Mosley

et al ., “Ceftazidime-Avibactam (Avycaz): For the Treatment of Complicated Intra-Abdominal and Uri-nary Tract Infections,” Pharmacy and Therapeutics 41, no. 8 (2016): 479.

15.

ECDC, Surveillance of Antimicrobial Consumption in Europe (2012), available at <https://ecdc.europa.eu/sites/portal/files/media/en/publications/Publications/antimicrobial-consumption-europe-esac-net-2012.pdf> (last visited Jan. 11, 2018).

16.

NORM/NORM-VET, Usage of Antimicrobial Agents and Occurrence of Antimicrobial Resistance in Norway (2015), available at <https://unn.no/Documents/Kompetansetjenester,%20-sentre%20og%20fagr%C3%A5d/NORM%20-%20Norsk%20overv%C3%A5kingssystem%20for%20anti-biotikaresistens%20hos%20mikrober/Rapporter/NORM_NORM-VET-2015.pdf> (last visited Jan. 11, 2018).

17.

Alberg

et al ., “Antibiotikabruk og infeksjoner i sykehjem,” Tidsskr Nor Laegeforen 137, no. 6 (2017): 424.

18.

Statens legemiddelverk, Legemiddelmangel og avregistre-ringer 2017: Råd til apotek og helsepersonell, available at <https://legemiddelverket.no/legemiddelmangel/legemiddelmangel-og-avregistreringer-2017-rad-til-apotek-og-helsepersonell> (last visited April 27, 2017).

19.

ECDC, Rapid Risk Assessment: Carbapenem-Resistant Enterobacteriaceae (2016), available at <https://ecdc.europa.eu/sites/portal/files/media/en/publications/Publications/carbapenem-resistant-enterobacteriaceae-risk-assessment-april-2016.pdf> (last visited January 11, 2018).

20.

Årdal

et al ., DRIVE-AB Final Report - Revitalizing the Antibiotic Pipeline: Stimulating Innovation While Driving Sustainable Use and Global Access (2018), available at <http://www.imi.europa.eu/projects-results/project-fact-sheets/drive-ab> (last visited January 24, 2018)

21.

Årdal

et al ., “An Antibiotic's Journey from Marketing Authorization to Use, Norway,” Bulletin of the World Health Organization 95, no. 3 (2017): 220.

22.

Central Drugs Standard Control Organization, List of New Drug Approved from 01-01-2017 to Till Date by New Drugs Division, available at <http://cdsco.nic.in/forms/list.aspx?lid=2034&Id=11> (last visited May 8, 2017).

23.

South African Medicine Price Registry, Database Of Medicine Prices 08th May 2017 (2017), available at <http://mpr.gov.za/PublishedDocuments.aspx> (last visited January 11, 2018).

24.

The World Bank, Health Expenditure, Public (% of GDP), available at <http://data.worldbank.org/indicator/SH.XPD.PUBL.ZS> (last visited May 2, 2017).

25.

M.-J.

Seya

et al ., “A First Comparison between the Consumption of and the Need for Opioid Analgesics at Country, Regional, and Global Levels,” Journal of Pain & Palliative Care Pharmacotherapy 25, no. 1 (2011): 6-18.